Shares of Rigel Pharmaceuticals (RIGL) have gained 7% over the past four weeks to close the last trading session at $18.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$33.67 indicates a potential upside of 82.3%.The average comprises six short-term price targets ranging from a low of $20 to a high of$57, with a standard deviation of $17.36. While the lowest estimate indica ...